Patents by Inventor Carlos Bais

Carlos Bais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10617755
    Abstract: This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: April 14, 2020
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • Patent number: 10456470
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: October 29, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • Patent number: 10364466
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 30, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Matthew Brauer, Mallika Singh, Maike Schmidt
  • Patent number: 10208355
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Thomas Sandmann
  • Publication number: 20180282417
    Abstract: Disclosed are methods for treating cancer (e.g., solid tumor cancers, lung cancer, bladder head and neck cancer) with an anti-PD-L1 antibody in a patient identified as being responsive to anti-PD-L1 antibody therapy by detecting a mutation in one or more disclosed circulating tumor DNA (ctDNA) markers. Also disclosed are methods for determining the efficacy of anti-PD-L1 therapeutic antibody treatment in a patient having lung cancer or bladder cancer comprising detecting variant allele frequency in ctDNA in plasma samples and determining the difference of the variant allele frequency in ctDNA between the first and at least second plasma samples, wherein a decrease in the variant allele frequency in the at least second plasma sample relative to the first plasma sample identifies the anti-PD-L1 antibody treatment as effective.
    Type: Application
    Filed: March 30, 2018
    Publication date: October 4, 2018
    Inventors: Brandon Higgs, Koustubh Ranade, Carlos Bais, Philip Brohawn, Michael Kuziora, Rajiv Raja
  • Publication number: 20170226198
    Abstract: The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 10, 2017
    Inventors: Yuanyuan XIAO, Carlos BAIS, YounJeong CHOI, Nicola C. CONSALVO
  • Publication number: 20170051360
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: November 8, 2016
    Publication date: February 23, 2017
    Inventors: Carlos BAIS, Richard BOURGON, Thomas SANDMANN
  • Publication number: 20150065781
    Abstract: This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.
    Type: Application
    Filed: August 27, 2014
    Publication date: March 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Carlos BAIS, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • Publication number: 20150064178
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Carlos BAIS, Richard Bourgon, Heidi Phillips, Thomas Sandmann
  • Publication number: 20140017233
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 16, 2014
    Inventors: Carlos BAIS, Matthew Brauer, Mallika Singh, Maike Schmidt
  • Publication number: 20110171231
    Abstract: The invention provides anti-PlGF antibodies and methods of using the same.
    Type: Application
    Filed: January 12, 2011
    Publication date: July 14, 2011
    Inventors: Carlos Bais, Krista McCutcheon
  • Publication number: 20110117083
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for monitoring the effectiveness of treatment of with VEGF antagonists. The invention also provides methods for identifying and treating patients who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: August 13, 2010
    Publication date: May 19, 2011
    Applicant: Genentech, Inc.
    Inventors: Carlos Bais, Mallika Singh, Joshua Kaminker, Matthew Brauer